PLX - Protalix BioTherapeutics Inc Stock Price, Fair Value and News

1.15USD-0.02 (-1.71%)Delayed

Market Summary

USD1.15-0.02

Delayed

-1.71%

PLX Stock Price

View Fullscreen

PLX RSI Chart

PLX Valuation

Market Cap

84.3M

Price/Earnings (Trailing)

12.31

Price/Sales (Trailing)

1.41

EV/EBITDA

5.5

Price/Free Cashflow

19.3

PLX Price/Sales (Trailing)

PLX Profitability

Operating Margin

62.28%

EBT Margin

11.35%

Return on Equity

22.99%

Return on Assets

7.62%

Free Cashflow Yield

5.18%

PLX Fundamentals

PLX Revenue

Revenue (TTM)

59.7M

Rev. Growth (Yr)

-60.91%

Rev. Growth (Qtr)

-64.26%

PLX Earnings

Earnings (TTM)

6.8M

Earnings Growth (Yr)

-46.76%

Earnings Growth (Qtr)

23.97%

Breaking Down PLX Revenue

Last 7 days

4.6%

Last 90 days

-21.8%

Trailing 12 Months

-46.3%

How does PLX drawdown profile look like?

PLX Financial Health

Current Ratio

1.38

Debt/Equity

0.68

Debt/Cashflow

0.29

PLX Investor Care

Shares Dilution (1Y)

12.08%

Diluted EPS (TTM)

0.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	59.7M	0	0	0
2023	41.1M	67.5M	63.6M	65.5M
2022	43.1M	45.4M	47.6M	47.6M
2021	52.6M	48.0M	49.3M	38.4M
2020	65.9M	64.6M	61.2M	62.9M
2019	40.1M	50.4M	64.0M	54.7M
2018	22.7M	18.4M	11.5M	34.2M
2017	11.4M	16.0M	18.9M	21.1M
2016	3.4M	3.8M	7.1M	9.2M
2015	3.7M	3.9M	4.2M	4.4M
2014	13.6M	13.8M	13.9M	3.5M
2013	34.6M	10.7M	9.3M	10.5M
2012	8.1M	33.5M	36.1M	34.9M
2011	9.6M	9.3M	7.2M	8.4M
2010	0	2.5M	4.6M	6.6M
2009	0	0	0	388.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Protalix BioTherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	bashan dror	acquired	-	-	263,960	president and ceo
Oct 19, 2023	bashan dror	bought	90,483	1.4025	64,516	president and ceo
Aug 15, 2023	rubin eyal	acquired	-	-	201,903	sr. vp and cfo
Aug 15, 2023	naos yaron	acquired	-	-	187,344	sr. vp, operations
Aug 15, 2023	bashan dror	acquired	-	-	800,000	president and ceo
Aug 15, 2023	hayon yael	acquired	-	-	35,115	vp, research & development
Jan 03, 2023	schwartz aharon	bought	155,815	1.4165	110,000	-
Apr 11, 2022	bashan dror	bought	102,000	1.5	68,000	president and ceo
Feb 25, 2022	rubin eyal	acquired	-	-	121,951	sr. vp and cfo
Feb 25, 2022	bashan dror	acquired	-	-	637,531	president and ceo

Which funds bought or sold PLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	0.33	-14,868	36,440	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-37.75	-10,872	8,564	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	630	630	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	13,210	13,210	-%
May 15, 2024	Altshuler Shaham Ltd	unchanged	-	-6,314	15,299	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	91.83	28,330	107,494	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-67.37	-16,334	4,905	-%
May 15, 2024	Squarepoint Ops LLC	new	-	22,447	22,447	-%
May 15, 2024	Lido Advisors, LLC	unchanged	-	-8,088	19,598	-%
May 15, 2024	Aptus Capital Advisors, LLC	added	5.93	-8,247	24,722	-%

Are Funds Buying or Selling PLX?

Are funds buying PLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PLX

No. of Funds

Unveiling Protalix BioTherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	nacht marius	2.9%	2,208,913	SC 13G/A
Jan 03, 2023	nacht marius	5.3%	2,816,901	SC 13G/A
Jun 09, 2022	whitebox advisors llc	5.65%	2,816,108	SC 13G
Feb 14, 2022	highbridge capital management llc	5.03%	2,414,487	SC 13G/A
Feb 11, 2022	highbridge capital management llc	0%	0	SC 13G/A
Jan 31, 2022	nacht marius	5.8%	2,816,901	SC 13G/A
Jul 30, 2021	burrage capital management llc	0%	0	SC 13G/A
Jun 15, 2021	dexcel pharma technologies ltd.	4.47%	2,034,117	SC 13G/A
Feb 16, 2021	ubs oconnor llc	3.2%	1,091,176	SC 13G/A
Feb 16, 2021	dexcel pharma technologies ltd.	10.30%	4,556,031	SC 13G/A

Recent SEC filings of Protalix BioTherapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	DEFA14A	DEFA14A
May 17, 2024	ARS	ARS
May 10, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 03, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report

Peers (Alternatives to Protalix BioTherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Protalix BioTherapeutics Inc News

Latest updates

Protalix BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-64.3%	3,748,000	10,486,000	10,345,000	35,075,000	9,588,000	8,617,000	14,183,000	8,753,000	16,085,000	8,549,000	12,054,000	6,427,000	11,320,000	19,495,000	10,790,000	10,967,000	21,646,000	17,759,000	14,248,000	12,247,000	10,439,000
Cost Of Revenue	-70.6%	2,602,000	8,856,000	4,893,000	6,148,000	3,085,000	2,397,000	7,074,000	4,087,000	6,034,000	3,148,000	3,703,000	4,733,000	4,765,000	2,752,000	2,868,000	1,827,000	3,426,000	2,950,000	3,205,000	2,695,000	2,045,000
S&GA Expenses	-24.8%	3,115,000	4,143,000	3,670,000	4,031,000	3,115,000	3,098,000	2,848,000	2,611,000	3,154,000	3,466,000	2,954,000	3,171,000	3,138,000	2,951,000	2,816,000	2,194,000	3,187,000	3,014,000	2,587,000	2,068,000	2,230,000
R&D Expenses	-6.9%	2,887,000	3,102,000	3,669,000	4,475,000	5,847,000	5,617,000	7,386,000	7,579,000	8,767,000	7,641,000	7,282,000	7,689,000	7,122,000	10,953,000	7,688,000	9,186,000	10,340,000	9,595,000	10,000,000	13,323,000	11,698,000
EBITDA Margin	-8.7%	0.17	0.19	0.25	0.21	-0.29	-0.23	-0.51	-0.53	-0.54	-0.60	-0.02	-0.02	-	-	-	-	-	-	-	-	-
Interest Expenses	76700.0%	766,000	-1,000	766,000	899,000	1,078,000	-	1,078,000	-	1,120,000	122,000	1,116,000	-	-	2,172,000	-	-	-	2,172,000	-	-	-
Income Taxes	63.9%	-138,000	-382,000	133,000	308,000	195,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	26.3%	-4,733,000	-6,426,000	-1,719,000	19,647,000	-2,936,000	-3,210,000	-3,567,000	-5,334,000	-2,286,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-13.2%	0.11	0.13	0.19	0.15	-0.37	-0.30	-0.58	-0.61	-0.64	-0.72	-0.13	-0.14	-	-	-	-	-	-	-	-	-
Net Income	24.0%	-4,595,000	-6,044,000	-1,852,000	19,339,000	-3,131,000	-3,740,000	-3,567,000	-5,334,000	-2,286,000	-6,667,000	-4,199,000	-11,241,000	-5,475,000	397,000	-4,437,000	-4,150,000	1,667,000	291,000	-3,560,000	-7,743,000	-7,264,000
Net Income Margin	-9.5%	0.11	0.13	0.17	0.13	-0.38	-0.31	-0.38	-0.41	-0.57	-0.72	-0.42	-0.43	-	-	-	-	-	-	-	-	-
Free Cashflow	7.3%	3,590,000	3,345,000	-7,335,000	4,769,000	-3,246,000	-2,824,000	-9,262,000	-7,484,000	-6,058,000	-5,535,000	-2,224,000	6,235,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	6.4%	90.00	84.00	88.00	88.00	67.00	56.00	57.00	61.00	68.00	74.00	83.00	108	103	68.00	72.00	72.00	83.00	45.00	54.00	55.00	61.00
Current Assets	7.8%	75.00	70.00	73.00	74.00	55.00	45.00	46.00	50.00	57.00	62.00	71.00	96.00	91.00	56.00	60.00	54.00	58.00	32.00	40.00	42.00	47.00
Cash Equivalents	15.1%	27.00	24.00	20.00	48.00	33.00	17.00	11.00	12.00	17.00	39.00	11.00	34.00	20.00	18.00	14.00	5.00	14.00	18.00	21.00	25.00	30.00
Inventory	17.3%	22.00	19.00	22.00	20.00	20.00	17.00	15.00	17.00	17.00	18.00	15.00	14.00	14.00	13.00	13.00	11.00	9.00	8.00	8.00	7.00	7.00
Net PPE	-3.9%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00
Liabilities	18.0%	60.00	51.00	49.00	49.00	66.00	66.00	68.00	71.00	76.00	80.00	83.00	104	88.00	95.00	106	106	114	116	125	123	121
Current Liabilities	20.4%	55.00	46.00	43.00	23.00	32.00	32.00	34.00	31.00	35.00	33.00	43.00	96.00	81.00	86.00	44.00	42.00	48.00	40.00	33.00	26.00	27.00
Long Term Debt	-	-	-	-	20.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	-	-	-	54.00	53.00	52.00	51.00	50.00	49.00	49.00
LT Debt, Current	0.8%	20.00	20.00	20.00	-	-	-	-	-	-	-	3.00	56.00	55.00	54.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	20.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	-	-	-	54.00	53.00	52.00	51.00	50.00	49.00	49.00
Shareholder's Equity	-11.3%	30.00	34.00	38.00	39.00	1.00	-10.64	-	-	-	-6.04	0.00	4.00	15.00	-27.04	-	-	-	-	-	-	-
Retained Earnings	100.0%	-	-381	-	-	-	-389	-	-	-	-374	-	-	-	-347	-	-	-	-340	-	-	-
Additional Paid-In Capital	-100.0%	-	415	-	-	-	379	-	-	-	369	-	-	-	320	-	-	-	270	-	-	-
Shares Outstanding	0.1%	73.00	73.00	66.00	67.00	57.00	54.00	49.00	47.00	46.00	44.00	46.00	43.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	139	-	-	-	52.00	-	-	-	85.00	-	-	-	121	-	-	-	68.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	16.5%	4,188	3,595	-6,888	4,973	-2,998	-2,611	-9,204	-7,356	-5,829	-5,087	-1,880	6,516	-9,834	-7,550	-3,604	-7,835	-7,117	-3,687	-3,225	-5,170	-7,276
Share Based Compensation	-28.2%	981	1,367	1,097	438	546	539	422	288	836	418	563	578	816	1,014	1,414	267	431	236	196	113	290
Cashflow From Investing	-77.2%	-606	-342	-20,879	-222	4,732	4,953	5,912	357	-16,257	37,436	4,629	7,540	-30,684	7,592	7,803	-268	-35,079	29.00	-446	-95.00	-371
Cashflow From Financing	-	-	-	-	10,433	14,233	4,075	1,520	-	-	-4,046	-25,990	-	42,114	4,652	4,472	-1,264	38,607	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PLX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
TOTAL REVENUE	$ 3,748	$ 9,588
COST OF GOODS SOLD	(2,602)	(3,085)
RESEARCH AND DEVELOPMENT EXPENSES	(2,887)	(5,847)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	(3,115)	(3,115)
OPERATING LOSS	(4,856)	(2,459)
FINANCIAL EXPENSES	(390)	(649)
FINANCIAL INCOME	513	172
FINANCIAL INCOME (EXPENSES), NET	123	(477)
LOSS BEFORE TAX BENEFIT (TAXES ON INCOME)	(4,733)	(2,936)
TAX BENEFIT (TAXES ON INCOME)	138	(195)
NET LOSS FOR THE PERIOD	$ (4,595)	$ (3,131)
LOSS PER SHARE OF COMMON STOCK - BASIC	$ (0.06)	$ (0.05)
LOSS PER SHARE OF COMMON STOCK - DILUTED	$ (0.06)	$ (0.05)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- BASIC	73,036,569	57,480,009
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- DILUTED	73,036,569	57,480,009
Goods
TOTAL REVENUE	$ 3,677	$ 5,066
License and R&D Services
TOTAL REVENUE	$ 71	$ 4,522

PLX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 27,209	$ 23,634
Short-term bank deposits	21,278	20,926
Accounts receivable - Trade	3,759	5,272
Other assets	812	1,055
Inventories	22,346	19,045
Total current assets	75,404	69,932
NON-CURRENT ASSETS:
Funds in respect of employee rights upon retirement	531	528
Property and equipment, net	4,781	4,973
Deferred income tax asset	3,230	3,092
Operating lease right of use assets	5,879	5,909
Total assets	89,825	84,434
Accounts payable and accruals:
Trade	3,146	4,320
Other	18,770	19,550
Operating lease liabilities	1,453	1,409
Contracts liability	11,039
Convertible notes	20,420	20,251
Total current liabilities	54,828	45,530
LONG TERM LIABILITIES:
Liability for employee rights upon retirement	712	714
Operating lease liabilities	4,499	4,621
Total long term liabilities	5,211	5,335
Total liabilities	60,039	50,865
COMMITMENTS
STOCKHOLDERS' EQUITY	29,786	33,569
Total liabilities and stockholders' equity	$ 89,825	$ 84,434

About Protalix BioTherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃƒÂ§ÃƒÂ£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

CEO	Mr. Dror Bashan
WEBSITE	protalix.com
INDUSTRY	Biotechnology
EMPLOYEES	193

Protalix BioTherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Protalix BioTherapeutics Inc? What does PLX stand for in stocks?

PLX is the stock ticker symbol of Protalix BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protalix BioTherapeutics Inc (PLX)?

As of Fri May 17 2024, market cap of Protalix BioTherapeutics Inc is 84.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers. The fair value of Protalix BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protalix BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protalix BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLX is over valued or under valued. Whether Protalix BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Protalix BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLX.

What is Protalix BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PLX's PE ratio (Price to Earnings) is 12.31 and Price to Sales (PS) ratio is 1.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Protalix BioTherapeutics Inc's stock?

In the past 10 years, Protalix BioTherapeutics Inc has provided -0.297 (multiply by 100 for percentage) rate of return.